In a boon to the pharmaceutical industry, the federal government moved to dismiss nearly a dozen lawsuits alleging drug makers devised schemes in which nurses were used illegally to promote their medicines and boost prescriptions, an arrangement that purportedly violated federal kickback laws.

In explaining its rationale, the U.S. Department of Justice argued the company that made the allegations was a “professional” whistleblower that used “false pretenses” to gather information for the “cloned” lawsuits. The feds complained that several investors created a company to file the lawsuits and pretended to conduct research studies in order to obtain information for their allegations, according to court documents in a case involving Bayer Pharmaceuticals (BAYRY).

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy